News

  • 22 February 2018

    Aimmune reports positive results in PALISADE trial

    Aimmune Therapeutics has reported that it has met its primary endpoint in a Phase III PALISADE trial, successfully evaluating the safety and efficacy of AR101 for the treatment of patients...